In this issue of JAMA, the Huntington Study Group (HSG), First-HD study investigators, reports findings from a randomized trial examining use of a deuterated form of tetrabenazine, called deutetrabenazine, for treatment of chorea in patients with Huntington disease.1 Tetrabenazine, a vesicular monoamine transporter type 2 inhibitor that depletes monoamines including dopamine, is used worldwide for the treatment of chorea and dystonia. Tetrabenazine was approved by the US Food and Drug Administration (FDA) for the treatment of chorea in Huntington disease, based on a prior HSG study.2
Geschwind MD, Paras N. Deutetrabenazine for Treatment of Chorea in Huntington Disease. JAMA. 2016;316(1):33–35. doi:10.1001/jama.2016.8011
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.